CG Oncology's Groundbreaking IPO Launches the Biopharmaceutical Industry into 2024

CG Oncology, a young biopharmaceutical company, has achieved an extraordinary milestone by successfully going public on the NASDAQ. Led by a 33-year-old Chinese-American executive, CG Oncology's debut has captured significant attention despite not having any commercialized products. The company's clinical-stage oncolytic virus therapy, Cretostimogene, attracted investors and raised an impressive $380 million in its initial public offering. This remarkable achievement sets a promising tone for the biopharmaceutical sector in 2024.

In a groundbreaking move, CG Oncology has made an impactful entry into the stock market. Founded in 2020, the company specializes in developing oncolytic immunotherapy for bladder cancer. CG Oncology recently announced its first public offering, consisting of 20 million shares priced at $19 per share. The company managed to raise a substantial $380 million in funding.

Trading on the NASDAQ began on January 25th, with CG Oncology listed under the ticker symbol "CGON." The stock opened at $29 per share, reflecting a 52.6% increase from the offering price. By the end of the trading day, the stock closed at $37.17 per share, marking an impressive 95.63% surge. This surge in stock value propelled the company's market capitalization to approximately $2.248 billion. The enthusiastic response from investors can be attributed to CG Oncology's pipeline, particularly its oncolytic virus therapy, Cretostimogene, designed to treat high-risk non-muscle invasive bladder cancer (NMIBC) patients who are unresponsive to Bacillus Calmette-Guérin (BCG) treatment.

Bladder cancer remains a significant health concern, with an estimated 82,000 new cases and 17,000 deaths projected in the United States by 2023. NMIBC, characterized by a high recurrence rate, poses a substantial challenge in treatment. Between 15% and 61% of high-risk NMIBC patients experience a recurrence within one year of treatment, while 31% to 78% of NMIBC patients experience recurrence or progression to muscle-invasive bladder cancer within five years, depending on risk factors[2]. The current standard treatment, BCG therapy, has limitations, including drug resistance and patients' reluctance to undergo radical cystectomy or complete bladder removal, highlighting the need for innovative treatment options.

Cretostimogene, CG Oncology's oncolytic virus therapy, has emerged as a breakthrough in addressing this unmet medical need. The company has conducted several clinical trials, including the Phase 3 BOND-003, Phase 2 CORE-001, and Phase 1 CORE-008 trials. The BOND-003 trial, evaluating the efficacy of Cretostimogene as a monotherapy for BCG-unresponsive high-risk NMIBC patients, showed promising results. Mid-term data from the trial reported a complete response rate of 75.7%, with 50 out of 66 patients achieving a complete response.

Notably, Cretostimogene demonstrated durable responses, with 74% of patients maintaining a complete response for at least six months. Additionally, during the second induction treatment period, 31% of non-responders achieved a treatment response. The combination of Cretostimogene with the PD-1 antibody Pembrolizumab further enhanced the therapeutic effect, resulting in an 85% complete response rate among the patients. Importantly, Cretostimogene exhibited an excellent safety profile, with no Grade 3 or higher adverse effects reported.

The ongoing BOND-003 trial is expected to report top-line data by the end of 2024. Positive results from this trial will provide the basis for CG Oncology to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Cretostimogene. Recognizing its remarkable efficacy and safety, Cretostimogene received Fast Track designation and Breakthrough Therapy designation from the FDA in December 2023 for the treatment of BCG-unresponsive high-risk NMIBC patients. It is worth mentioning that Leap Therapeutics acquired the Greater China rights to CG0070, a similar oncolytic virus therapy developed by CG Oncology, in March 2019. Leap Therapeutics also holds the rights to sublicense the therapy to other companies in Greater China, South Korea, and Southeast Asia, further expanding its market potential.